InvestorsHub Logo
Followers 22
Posts 1964
Boards Moderated 0
Alias Born 06/15/2005

Re: None

Wednesday, 11/15/2017 2:12:12 PM

Wednesday, November 15, 2017 2:12:12 PM

Post# of 8923
Very good trial results. Conference Call @ 4:30 p.m. today for those that want to listen. Only posted 1st part of press release.

Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor's Investigational Cell Therapy





•November 15, 2017

Comment




Dr. Ronald G. Victor Presents 12-Month Results of HOPE Clinical Trial at AHA Late-Breaking Session

Company to Host Conference Call and Webcast Today at 4:30 p.m. ET

ANAHEIM, Calif., Nov. 15, 2017 /PRNewswire/ -- Boys and young men in advanced stages of Duchenne muscular dystrophy experienced significant and sustained improvements in cardiac structure and function, as well as skeletal muscle function, following treatment with CAP-1002, the lead investigational therapy under development at Capricor Therapeutics (CAPR). These findings were reported today by Ronald G. Victor, M.D. at a Late-Breaking Science session of the American Heart Association Scientific Sessions 2017.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CAPR News